What is Assertio?
Founded in 1995, Assertio is a commercial pharmaceutical company dedicated to the development and marketing of branded prescription medications. The company's therapeutic focus spans neurology, inflammation, and pain management, with a strategic approach to portfolio expansion through acquisitions and licensing. Assertio maintains a global operational footprint, serving markets across North America, Europe, and Asia, and is committed to delivering differentiated pharmaceutical products to patients worldwide.
How much funding has Assertio raised?
Assertio has raised a total of $41.5M across 2 funding rounds:
Stock Offering
$7.2M
Share Placement
$34.3M
Stock Issuance/Offering (1997): $7.2M, investors not publicly disclosed
Share Placement (2021): $34.3M, investors not publicly disclosed
What's next for Assertio?
The recent major strategic investment signals a pivotal phase for Assertio, likely enabling accelerated expansion of its product pipeline and market reach. This infusion of capital is expected to fuel further research and development initiatives, potentially leading to new therapeutic breakthroughs and enhanced patient care. Assertio's continued focus on strategic acquisitions and licensing will likely remain a cornerstone of its growth strategy, solidifying its position in key therapeutic areas.
See full Assertio company page
